SHE: 002317

Company Drug

Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential

Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line results from its Phase IIb...

Company Deals

Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million

Fineline Cube Feb 10, 2026

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has entered a strategic licensing agreement with Qilu...

Company Drug

Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials

Fineline Cube Feb 9, 2026

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced positive top-line results from two Phase III...

Company Drug

Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up

Fineline Cube Jan 26, 2026

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Zhongsheng’s Onradivir Granules Enroll First Phase 3 Pediatric Influenza Patient

Fineline Cube Nov 24, 2025

Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced the enrollment and dosing of the first...

Company Drug

Zhongsheng Pharma’s Onradivir Granted Drug Registration in Macau

Fineline Cube Aug 22, 2025

Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced that its onradivir tablets have received a...

Company Deals

Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau

Fineline Cube Aug 5, 2025

On August 5, 2025, China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with...

Company Drug

Zhongsheng Pharma’s RAY1225 Enters Phase III Trial for Obesity/Overweight Treatment

Fineline Cube Jun 20, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the initiation of the multi-center, randomized,...

Company Drug

Guangdong Zhongsheng Wins Peking University People’s Hospital Nod for RAY1225 Phase III Trials

Fineline Cube May 26, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval from...

Company Drug

Zhongsheng Pharma’s Anruiwei Receives NMPA Approval for Influenza A

Fineline Cube May 23, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received marketing approval...

Company Drug

Zhongsheng Pharma’s Anruiwei Shows Promising Results in Pediatric Influenza A Study

Fineline Cube May 14, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the topline analysis data from the...

Company Drug

Zhongsheng Pharma’s RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction

Fineline Cube May 7, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line analysis results from dose...

Company Medical Device

Zhongsheng Pharmaceutical’s RAY1225 Gets Green Light for Phase III Study

Fineline Cube Feb 28, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval in...

Company Drug

Zhongsheng Pharma Gains FDA Approval for Phase II Study of RAY1225

Fineline Cube Feb 8, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval from...

Company Drug

Guangdong Zhongsheng Pharmaceutical’s RAY1225 Shows Positive Results in Phase II Study

Fineline Cube Nov 21, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based pharmaceutical company, has announced positive top-line...

Company Drug

Guangdong Zhongsheng Pharmaceutical’s COVID-19 Drug Leritrelvir Approved in Macau

Fineline Cube Aug 12, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a pharmaceutical company based in China, has announced...

Company Drug

Guangdong Zhongsheng Reports Positive Phase I Results for Innovative Weight Loss Drug RAY1225

Fineline Cube Mar 26, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based biopharmaceutical company, has announced promising top-line...

Company Drug

Zhongsheng Pharmaceutical Initiates Phase II Trials for Polypeptide Drug RAY1225 in Diabetes and Obesity

Fineline Cube Feb 22, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a Chinese pharmaceutical company, has announced the initiation...

Company Drug

Guangdong Zhongsheng Pharmaceutical’s ZSP1273 for Influenza A Accepted for Review by NMPA

Fineline Cube Dec 27, 2023

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a Chinese pharmaceutical company, has announced that China’s...

Company Drug

Guangdong Zhongsheng Launches AI Q&A Bot for Leritrelvir Drug Support

Fineline Cube Oct 19, 2023

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the innovative launch of a...

SHE: 002317

Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential

Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million

Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials

Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up

Zhongsheng’s Onradivir Granules Enroll First Phase 3 Pediatric Influenza Patient

Zhongsheng Pharma’s Onradivir Granted Drug Registration in Macau

Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau

Zhongsheng Pharma’s RAY1225 Enters Phase III Trial for Obesity/Overweight Treatment

Guangdong Zhongsheng Wins Peking University People’s Hospital Nod for RAY1225 Phase III Trials

Zhongsheng Pharma’s Anruiwei Receives NMPA Approval for Influenza A

Zhongsheng Pharma’s Anruiwei Shows Promising Results in Pediatric Influenza A Study

Zhongsheng Pharma’s RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction

Zhongsheng Pharmaceutical’s RAY1225 Gets Green Light for Phase III Study

Zhongsheng Pharma Gains FDA Approval for Phase II Study of RAY1225

Guangdong Zhongsheng Pharmaceutical’s RAY1225 Shows Positive Results in Phase II Study

Guangdong Zhongsheng Pharmaceutical’s COVID-19 Drug Leritrelvir Approved in Macau

Guangdong Zhongsheng Reports Positive Phase I Results for Innovative Weight Loss Drug RAY1225

Zhongsheng Pharmaceutical Initiates Phase II Trials for Polypeptide Drug RAY1225 in Diabetes and Obesity

Guangdong Zhongsheng Pharmaceutical’s ZSP1273 for Influenza A Accepted for Review by NMPA

Guangdong Zhongsheng Launches AI Q&A Bot for Leritrelvir Drug Support

You Missed

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance